Regenerative Bone
Medicine Company
This company was launched to develop and commercialize a class of drugs based on targeting mesenchymal stem cells (MSCs) to various sites of clinical relevance. The company's new findings have currently been demonstrated in a number of animal models for osteonecrosis, fracture healing, osteoporosis, and inflammatory arthritis. The potential opportunity for this company is to develop these drugs addressing a need for effective stem cell treatments in osteonecrosis, fracture healing, osteoporosis, and inflammatory arthritis.